Isarna Therapeutics (Germany)

First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery

Norbert Pfeiffer, Bogomil Voykov, Giulia Renieri et al. · PLoS ONE · 2017 · 67 citations · Full text

TGF-β1 and TGF-β2 abundance in liver diseases of mice and men

Anne Dropmann, T. Dediulia, Katja Breitkopf‐Heinlein et al. · Oncotarget · 2016 · 59 citations · Full text

Tgf-β2 Expression, Immunology, Pathology +20

Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma

Katharina Seystahl, Alexandros Papachristodoulou, Isabel Burghardt et al. · Molecular Cancer Therapeutics · 2017 · 57 citations

Novel Three-Pronged Strategy to Enhance Cancer Cell Killing in Glioblastoma Cell Lines: Histone Deacetylase Inhibitor, Chemotherapy, and Oncolytic Adenovirus dl520

Alexa Bieler, Klaus Mantwill, Tanja Dravits et al. · Human Gene Therapy · 2006 · 49 citations

Cell Death, Cancer Biology, Glioma +18

Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas

Alexandros Papachristodoulou, Manuela Silginer, Michael Weller et al. · Clinical Cancer Research · 2019 · 48 citations